Safety and efficacy of 125 I radioactive seed strand implantation combined with transjugular intrahepatic portosystemic shunt for portal hypertension accompanied by portal vein tumor thrombus
World Journal of Gastrointestinal Surgery · 2026-11-27 · 18 (11)
DOI: 10.4240/wjgs.123917 ↗Abstract
BACKGROUND In patients with cirrhotic portal hypertension complicated by portal vein tumor thrombus (PVTT) secondary to hepatocellular carcinoma, satisfactory therapeutic efficacy and long-term prognosis remain difficult to achieve with transjugular intrahepatic portosystemic shunt (TIPS) alone. A combined strategy incorporating portal vein implantation of radioactive 125I seed strands represents a therapeutic paradigm warranting thorough investigation. AIM To evaluate the safety and efficacy of 125I radioactive seed strand implantation combined with TIPS in patients with portal hypertension and PVTT. METHODS Clinical data from 187 consecutive patients with portal hypertension and PVTT treated at our institution between January 2019 and December 2023 were retrospectively analyzed. Ultimately, 116 eligible patients were enrolled and divided into the TIPS-alone group (n = 56) and the TIPS combined with 125I seed strand implantation group (n = 60). Perioperative technical parameters, symptom relief rates, stent restenosis time, and survival outcomes were compared between the two groups. Patients were followed until death or loss to follow-up (median follow-up: 22.6 months, range: 1.2-65.7 months). Survival analysis was performed using the Kaplan-Meier method, and multivariate Cox proportional hazards regression was employed to identify independent prognostic factors. RESULTS The technical success rate was 100%. The postoperative portal pressure gradient was significantly reduced compared with baseline (P < 0.001). The median overall survival was 13.93 months [95% confidence interval (CI): 10.03-15.97] in the combined group, which was significantly longer than the 8.99 months (95%CI: 6.45-11.53) observed in the TIPS-alone group (P = 0.0034). The cumulative survival rates at 6, 12, and 24 months were 88.33%, 53.33%, and 26.67% in the combined group, compared with 69.64%, 28.57%, and 12.5% in the control group, respectively. The symptom relief rate was markedly higher, and the stent restenosis rate was significantly lower in the combined group (hazard ratio = 0.227, 95%CI: 0.129-0.401, P < 0.001). Multivariate Cox regression analysis identified 125I seed strand implantation, Child-Pugh class, and Model for End-Stage Liver Disease score as independent prognostic factors (all P < 0.05). CONCLUSION The combination of 125I radioactive seed strand implantation and TIPS is a safe and effective therapeutic strategy for patients with portal hypertension and PVTT, prolonging survival and reducing stent restenosis.
EUVIMED